Every 10-Q that Envoy Medical (COCH) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow COCH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full COCH filings page.
Envoy Medical, Inc. develops fully implanted hearing devices and remains a pre-revenue, development-stage company centered on its investigational Acclaim cochlear implant. For the three and six months ended June 30, 2026, it generated only $51k and $90k of net revenue, respectively, primarily from legacy Esteem implant components, while recording net losses of $5.98M and $10.33M.
Research and development spending was substantial at $3.13M for the quarter and $6.77M year-to-date, driving an operating loss of $11.53M for the first half. Operating cash outflow was $11.52M, but cash increased to $19.68M at June 30, 2026 from $3.74M at year-end, mainly due to the February 2026 equity offering, which raised $29.997M gross and $27.78M net and expanded Class A shares outstanding to 77.2M. Numerous warrants and preferred shares create a sizable potential dilution overhang.
Management explicitly states that existing cash is not sufficient to fund operations for 12 months after issuance of these financial statements, concluding that substantial doubt exists about the company’s ability to continue as a going concern. Plans rely on additional financing and potential warrant exercises. Clinically, all 56 pivotal Acclaim cochlear implant trial participants have been enrolled and activated, the first 10 have reached 12-month follow-up, all 56 have passed the 3‑month milestone, and the first module of the Premarket Approval application was submitted to the FDA.
Envoy Medical reported a Q1 2026 net loss of $4,351, slightly improved from $4,998 a year earlier, on very modest net revenue of $39. Operating expenses rose to $5,998, driven mainly by research and development for its fully implanted Acclaim cochlear implant.
Cash jumped to $25,251 from $3,739 at year-end 2025, after the February 2026 equity offering raised net proceeds of $27,782. That deal issued 47.9 million common shares, 27.1 million pre-funded warrants, and 120 million-plus Series A warrants.
Despite the stronger balance sheet, Envoy still discloses “substantial doubt” about its ability to continue as a going concern, citing ongoing losses and dependence on future financings and warrant exercises. The company ended the quarter with an accumulated deficit of $319,097 and 76,881,110 Class A shares outstanding.
Envoy Medical (COCH) filed its Q3 2025 10-Q, reporting net revenues of $42 thousand and an operating loss of $5.708 million. Net loss was $6.482 million, or $0.35 per share. Cash was $3.556 million as of September 30, 2025.
The company eliminated related-party debt via a satisfaction agreement, recording a $27.879 million capital contribution to additional paid-in capital and improving total stockholders’ deficit to $7.661 million. Management states that recurring losses and limited cash raise substantial doubt about the company’s ability to continue as a going concern.
During the quarter, Envoy completed a registered direct offering of 1,908,402 shares for gross proceeds of $2.5 million and issued 5,725,206 Investor Warrants, recognized as a liability measured at fair value. An at-the-market program added $414 thousand year-to-date. The FDA granted an IDE in October 2024 to begin a pivotal study of the fully implanted Acclaim cochlear implant, while the Esteem device continues to generate modest revenue.